Samith T. Kochuparambil
Expertise in
46
conditions

Dr. Samith T. Kochuparambil

Hematology Oncology
Minnesota Oncology Hematology PA - Minneapolis
910 East 26th Street, Suite 200, 
Minneapolis, MN 
Accepting New Patients
Offers Telehealth
Expertise in
46
conditions
Minnesota Oncology Hematology PA - Minneapolis
910 East 26th Street, Suite 200, 
Minneapolis, MN 

Overview

Samith Kochuparambil is a Hematologist Oncology provider practicing medicine in Minneapolis, Minnesota.

Dr. Kochuparambil is highly rated in 46 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Adult Soft Tissue Sarcoma, and Bone Marrow Aspiration.

Dr. Kochuparambil is board certified in 2014, Hematology, Internal Medicine, Medical Oncology, and American Board Of Internal Medicine,2015. He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 6 clinical trials. Dr. Kochuparambil is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in MN

Board Certifications

2014
Hematology
Internal Medicine
Medical Oncology
American Board Of Internal Medicine,2015

Hospital Affiliations

M Health Fairview Southdale Hospital
Abbott Northwestern Hospital
Allina Health Faribault Medical Center

Languages Spoken

English
Hindi
Malayalam
Tamil

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Metropolitan Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Minnesota Oncology Hematology PA - Minneapolis
910 East 26th Street, Suite 200, Minneapolis, MN 55404

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2026
Intervention Type: Drug
Study Drug: Avelumab
Study Phase: Phase 3
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
A Phase Ib Open-Label, Dose-Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: September 20, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Combination product
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

13 Total Publications

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.
Journal: Nature communications
Published: July 25, 2025
Similar Doctors
Expertise in
29
conditions
Dr. Veronika Bachanova
Hematology Oncology
Expertise in
29
conditions
Dr. Veronika Bachanova
Hematology Oncology
Referral may be required

M Health Fairview Blood And Marrow Transplant Program Minneapolis

909 Fulton Street Southeast, Suite 214, 
Minneapolis, MN 
 (1.5 miles away)
612-676-4200
Languages Spoken:
English, Czech, Russian, Slovak
See accepted insurances
Accepting New Patients
Offers Telehealth

Veronika Bachanova is a Hematologist Oncology provider practicing medicine in Minneapolis, Minnesota. Dr. Bachanova is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bachanova is board certified in Hematology: American Board Of Internal Medicine, 2008. Dr. Bachanova is currently accepting new patients.

Expertise in
25
conditions
Dr. Greg M. Vercellotti
Hematology Oncology | Hematology
Expertise in
25
conditions
Dr. Greg M. Vercellotti
Hematology Oncology | Hematology
Referral may be required

M Health Fairview Blood And Marrow Transplant Program Minneapolis

909 Fulton Street Southeast, Suite 214, 
Minneapolis, MN 
 (1.5 miles away)
612-676-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Greg Vercellotti is a Hematologist Oncology specialist and a Hematologist practicing medicine in Minneapolis, Minnesota. Dr. Vercellotti is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vercellotti is board certified in Hematology: American Board Of Internal Medicine, 1982 and Internal Medicine: American Board Of Internal Medicine, 1979. Dr. Vercellotti is currently accepting new patients.

Expertise in
78
conditions
Dr. Vladimir Hugec
Hematology Oncology
Expertise in
78
conditions
Dr. Vladimir Hugec
Hematology Oncology
Referral may be required

Minnesota Oncology Hematology PA - Maplewood

1580 Beam Avenue, 
Maplewood, MN 
 (12.1 miles away)
651-779-7978
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vladimir Hugec is a Hematologist Oncology provider practicing medicine in Maplewood, Minnesota. Dr. Hugec is highly rated in 78 conditions, according to our data. His clinical expertise encompasses Severe Congenital Neutropenia, Chronic Familial Neutropenia, Agranulocytosis, Lung Cancer, and Pancreaticoduodenectomy. Dr. Hugec is board certified in American Board Of Internal Medicine,2006 and Medical Oncology. Dr. Hugec is currently accepting new patients.

Frequently Asked Questions about Dr. Samith T. Kochuparambil

How do I make an appointment with Dr. Samith T. Kochuparambil?

You can book an appointment with Dr. Samith T. Kochuparambil by calling their office at 612-884-6300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Samith T. Kochuparambil a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Samith T. Kochuparambil is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Samith T. Kochuparambil specialize in?

While Dr. Samith T. Kochuparambil is a Hematology Oncology, they have specific expertise in Multiple Myeloma, Non-Muscle Invasive Bladder Cancer, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Samith T. Kochuparambil participate in research or clinical trials?

Yes. Dr. Samith T. Kochuparambil has published 13 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Samith T. Kochuparambil's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Samith T. Kochuparambil accept my insurance?

Dr. Samith T. Kochuparambil accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 612-884-6300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kochuparambil's expertise for a condition
ConditionClose
    View All 43 Advanced Conditions
    View All 145 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile